Items Tagged ‘Breast Cancer’

November 15th, 2016

Aromatase Inhibitor–Associated Joint Pain Tends to Resolve Upon Treatment Completion

By

A class of drugs known as aromatase inhibitors (AI) commonly used in the management of estrogen receptor-positive (ER+) breast cancer are associated with troublesome joint pain. In fact, as many as half of women on AI therapy experience joint pain, and 20% become non-compliant with their AI therapy because of side effects.1 The origin of […]

View full entry

Tags: AI, aromatase inhibitors, Breast Cancer, ER-positive, joint pain, News


October 26th, 2016

Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer

By

The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole) for the initial treatment of postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer leads to improved survival without cancer recurrence. The interim results from a large clinical trial presented at the 2016 European Society for Medical Oncology (ESMO) meeting and published in the […]

View full entry

Tags: 2016, Breast Cancer, ESMO, Femera, hormone-receptor positive, HR+ metastatic, letrozole, Metastatic Breast Cancer, MONALEESA-2 clinical, News, ribociclib LEE011


September 7th, 2016

MammaPrint Might Help Identify Breast Cancer Patients Who Could Safely Opt Out of Chemo

By

MammaPrint, a 70-gene signature test, might help healthcare providers and patients determine whether they will derive a benefit from chemotherapy, or if they could safely choose to not receive chemotherapy for early-stage breast cancer. These results need to be validated, and compared to other tests in order to confirm findings and determine true clinical utility […]

View full entry

Tags: Breast Cancer, early-stage, hereditary, MammaPrint, News, Stage I Node Negative Breast Cancer


September 5th, 2016

ASCO Treatment Recommendations for HR+, Metastatic Breast Cancer

By

The American Society of Clinical Oncology (ASCO) recently convened an Expert Panel to create recommendations for endocrine therapy for women with hormone-receptor (HR)-positive, metastatic breast cancer. The panel conducted “a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence.” These updates were recently published in the Journal of Clinical […]

View full entry

Tags: Breast Cancer, Endocrine therapy, hormone-receptor (HR)-positive, hormones, metastatic, Metastatic Breast Cancer, News, recommendation


July 27th, 2016

Neratinib Improves Cancer-Free Survival in Early Breast Cancer

By

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is referred to as human epidermal growth factor receptor-2 (HER2)-positive.  This means that the breast cancer cells have too many HER2 proteins on […]

View full entry

Tags: Breast Cancer, early breast cancer, exteNET, HER2-positive, herceptin, neratinib, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, trastuzumab. her2


July 8th, 2016

It’s in the Genes: Top 5 Things to Know about Genetic Testing

By

Advances in genetic testing are offering women more information than ever before about their genetic makeup and are providing opportunities for empowered decision-making related to a wide range of health issues. In this recurring column, experts provide vital information about how genetic testing suits one’s individual needs, potential risks and benefits, and the role of […]

View full entry

Tags: Breast Cancer, Health and Wellness, News, Screening/Prevention Breast Cancer, Types of Cancer


June 30th, 2016

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer

By

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with advanced triple-negative breast cancer (TNBC). These results were recently reported at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Approximately 10-20% of breast cancers are referred to […]

View full entry

Tags: Breast Cancer, immunotherapy, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Tecentriq, tnbc, Triple Negative Breast Cancer


June 22nd, 2016

Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study

By

A clinical study to accelerate research in metastatic breast cancer has rapidly enrolled participants through direct collaboration with patients. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). One large challenge in furthering research in the field of cancer is obtaining enough samples of tumor tissue […]

View full entry

Tags: Breast Cancer, clinical study, Metastatic Breast Cancer, News, Recurrent Breast Cancer


June 7th, 2016

Treatment with Aromatase Inhibitors for 10 Years Improves Cancer-Free Survival in Breast Cancer

By

Among postmenopausal women with hormone-positive, early breast cancer, treatment with aromatase inhibitors (AIs) for 10 years significantly improves cancer-free survival, compared to the 5-year standard length of AI treatment.  However, quality of life issues, bone density concerns, and a patient’s risk of a recurrence should be taken into consideration to determine the optimal length of […]

View full entry

Tags: AIs, aromatase inhibitors, Breast Cancer, early-stage, hormone-positive, HR+, News, postmenopausal, Stage I Node Negative Breast Cancer, survival


June 7th, 2016

Abemaciclib Promising in Advanced Breast Cancer

By

The investigative agent abemaciclib, which is still in clinical trials, appears promising in providing anti-cancer activity among patients with metastatic breast cancer that has progressed following several prior therapies. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology. Metastatic breast cancer (MBC) refers to cancer that has […]

View full entry

Tags: 2016, abemaciclib, asco, Breast Cancer, HER2-negative, HR-positive, MBC, Metastatic Breast Cancer, MONARCH 1 trial, News


May 31st, 2016

Meditation versus Pain, Anxiety, and Fatigue during Breast Cancer Biopsy

By

By Helen Young Elsewhere in breast cancer news, meditation has been found to reduce symptoms of anxiety, tiredness, and pain for women having a breast cancer biopsy. Image-guided needle biopsies are highly efficient at diagnosing breast cancer, yet they can be painful and can cause a range of emotions that result in anxiety – everything […]

View full entry

Tags: anger, anxiety, biopsies, Breast Cancer, fear, meditation, News, Yoga


May 30th, 2016

New Breakthrough May Advance Triple Negative Breast Cancer Treatment

By

By Helen Young Scientists at The Scripps Research Institute have developed a new drug candidate that lowers the growth rate of tumor cells in animal models1 in one of the most difficult cancers to battle: triple negative breast cancer. This is the first time that scientists have been able to take a genetic sequence and design […]

View full entry

Tags: Breast Cancer, genetic sequence, microRNA, microRNA-96, News, RNA, Targaprimir-96, targeted therapy, Triple Negative Breast Cancer


May 25th, 2016

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk

By

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its expansion into the oncology market, with a focus on advancing cancer risk screening and helping cancer prevention efforts. Counsyl’s […]

View full entry

Tags: asco, ASCO16, ASCO2016, BRCAtesting, breast, Breast Cancer, breastcancerawareness, colon, Colon Cancer, DNAtesting, genetic testing, inherited cancer screen


April 28th, 2016

Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen

By

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently published in the Journal of Clinical Oncology. The majority of breast cancers, referred to as hormone-positive breast cancers, […]

View full entry

Tags: aromasin, Breast Cancer, exemestane, HER2-negative, hormone-positive, News, premenopausal, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, tamoxifen


March 31st, 2016

3D Mammography Proves More Accurate in Breast Cancer Detection

By

Longer follow-up evaluating digital breast tomosynthesis (DBT), also referred to as 3D mammography, demonstrates its continued effectiveness compared to standard digital mammography (DM) when screening for breast cancer. These results were recently published in JAMA Oncology. It is well established that survival rates for treatment of early breast cancer are significantly superior to survival rates […]

View full entry

Tags: 3D, Breast Cancer, digital breast tomosynthesis, mammography, News, screening, Screening/Prevention Breast Cancer